GSK's position on Flovent

At GSK, our priority is — and always has been — the health of patients, especially children and families living with asthma.
In line with common industry practice, GSK strategically reevaluates its portfolio over time, which may include decisions around discontinuing branded products or launching authorized generics. When transitions occur, our goal is to minimize disruptions for patients and approach any changes in medicines with that in mind.
In May 2022, GSK launched an authorized generic (AG) of Flovent HFA (fluticasone propionate), an inhaled treatment for asthma. The AG is a product that is the same as the brand. It was made available to patients through another company (Prasco) as the branded product reached the end of its patent life.
Changes resulting from Congress’ passage of the American Rescue Plan Act, meant it was no longer financially viable for GSK to continue offering its branded medicine, Flovent HFA (fluticasone propionate), as an inhaled treatment for asthma.

Therefore, in October 2022, GSK made the commercial decision to discontinue branded Flovent HFA, effective January 1st, 2024, after nearly 30 years on the market.
Prior to withdrawing Flovent HFA from the market, GSK implemented a 1.5-year transition period where both the authorized generic and branded Flovent HFA were available, allowing patients extended time for a smooth transition.
We recognize this transition led to unintended early disruptions in access for some patients due to certain financial decisions made by PBMs not to cover the authorized generic.
These decisions were outside of GSK’s control as Prasco independently manages coverage and pricing discussions with health plans and PBMs, including rebate structures for branded versus authorized generics. GSK is legally prohibited from influencing or directing those decisions.

To mitigate these unexpected challenges, and support continued patient access, starting in Dec 2024, we began supplying free product for eligible patients, including children, with financial needs through Prasco’s patient assistance program, which can be aaccessed at https://prasco.com/products-and-savings/patient-assistance/
Through Prasco’s patient assistance program, GSK has fulfilled all requests from Prasco, providing Flovent AG products free of charge, and continues to do so.
More recently, another company has received FDA approval to launch a generic version of Flovent HFA, which should result in even more patient access.
Moving forward, we remain strongly committed to working with healthcare professionals, patient advocates, and policymakers on this issue, to help ensure patient access is maintained.

Media contact

Kathleen K. Quinn, Vice President, US Corporate Media Relations and Digital Communications